Defauw J M, Murphy M M, Jagdmann G E, Hu H, Lampe J W, Hollinshead S P, Mitchell T J, Crane H M, Heerding J M, Mendoza J S, Davis J E, Darges J W, Hubbard F R, Hall S E
Sphinx Pharmaceuticals, a Division of Eli Lilly and Company, Durham, North Carolina 27707, USA.
J Med Chem. 1996 Dec 20;39(26):5215-27. doi: 10.1021/jm960581w.
A series of balanol analogs in which the perhydroazepine ring and the p-hydroxybenzamide moiety were combined into an acyclic linked unit have been prepared and evaluated for their inhibitory properties against the serine/threonine kinase PKC. Several low-micromolar to low-nanomolar inhibitors of the alpha, beta I, beta II, gamma, delta, epsilon and eta PKC isozymes were prepared. In general, these acyclic balanol analogs were found to be highly selective for PKC over the serine/threonine kinase PKA. The type and number of atoms linking the benzophenone ester to the p-hydroxyphenyl group necessary for optimal PKC inhibition were investigated. The most potent compounds contained a three-carbon linker in which the carboxamide moiety of balanol had been replaced by a methylene group. The effect of placing substituents on the three-carbon chain was also investigated. The preferred compounds contained either a 2-benzenesulfonamido (6b) or a 1-methyl (21b) substituent. The preferred compounds 6b and 21b were tested against a panel of serine/threonine kinases and found to be highly selective for PKC. The more active enantiomer of 6b, (S)-12b, was 3-10-fold more active than the R-enantiomer against the PKC isozymes. The effect of making the analogs more rigid by making the three-carbon chain part of a five-membered ring, but with retention of the methylene replacement for the carboxamide moiety, led to potent PKC inhibitors including anti-substituted pyrrolidine analog 35b and the most potent PKC inhibitor in the series, anti-substituted cyclopentane analog 29b. The anti cyclopentane analog 29b, was a low-micromolar inhibitor of the PMA-induced superoxide burst in neutrophils, and its carboxylic ester was a high-nanomolar inhibitor of neutrophils. Finally esterification of 21b, (S)-12b, and 35b turned these potent PKC inhibitors into low-micromolar inhibitors of neutrophils.
已制备了一系列将全氢氮杂卓环和对羟基苯甲酰胺部分组合成无环连接单元的巴拉诺醇类似物,并对其抑制丝氨酸/苏氨酸激酶PKC的性能进行了评估。制备了几种对α、βI、βII、γ、δ、ε和ηPKC同工酶具有低微摩尔至低纳摩尔抑制活性的抑制剂。一般来说,这些无环巴拉诺醇类似物对PKC的选择性远高于丝氨酸/苏氨酸激酶PKA。研究了连接二苯甲酮酯与对羟基苯基以实现最佳PKC抑制所需的原子类型和数量。最有效的化合物含有一个三碳连接基,其中巴拉诺醇的羧酰胺部分被亚甲基取代。还研究了在三碳链上引入取代基的影响。优选的化合物含有2-苯磺酰胺基(6b)或1-甲基(21b)取代基。对优选的化合物6b和21b针对一组丝氨酸/苏氨酸激酶进行了测试,发现它们对PKC具有高度选择性。6b的活性更高的对映体(S)-12b对PKC同工酶的活性比对映体R-12b高3至10倍。通过使三碳链成为五元环的一部分来使类似物更刚性,但保留亚甲基取代羧酰胺部分,得到了有效的PKC抑制剂,包括反式取代的吡咯烷类似物35b和该系列中最有效的PKC抑制剂反式取代的环戊烷类似物29b。反式环戊烷类似物29b是佛波酯诱导的中性粒细胞超氧化物爆发的低微摩尔抑制剂,其羧酸酯是中性粒细胞的高纳摩尔抑制剂。最后,21b、(S)-12b和35b的酯化将这些有效的PKC抑制剂转变为中性粒细胞的低微摩尔抑制剂。